Study ID | Intervention(s) and comparator(s) | Participants included in analysis (n) | Participants with at least one hypoglycaemic episode (n) | Participants with at least one hypoglycaemic episode (%) | Participants with at least one nocturnal hypoglycaemic episode (n) | Participants with at least one nocturnal hypoglycaemic episode (% participants) | Participants with at least one severe/serious hypoglycaemic episode (n) | Participants with at least one severe/serious hypoglycaemic episode (%) |
Bartley 2008 | I: detemir | 331 | 309 | 93.4 | 237 | 71.6 | 49 | 14.8 |
C: NPH | 164 | 159 | 97.0 | 124 | 75.6 | 42 | 25.6 | |
BEGIN Basal‐Bolus Type 1 | I: degludec | 472 | 451 | 96 | 341 | 72 | 58a | 12 |
C: glargine | 154 | 147 | 95 | 114 | 74 | 16 | 10 | |
BEGIN Flex T1 | I: degludec | 165 | 164 | 99.4 | 121 | 73.3 | 21 | 12.7 |
C: glargine | 161 | 156 | 96.9 | 117 | 72.6 | 16 | 9.9 | |
BEGIN Young | I: degludec | 174 | 171 | 98.3 | 133 | 76.4 | 31 | 17.8 |
C: detemir | 175 | 168 | 96.0 | 125 | 71.4 | 24 | 13.8 | |
Bolli 2009 | I: glargine | 90 | — | — | — | — | — | — |
C: NPH | 85 | — | — | — | — | — | — | |
Chase 2008 | I: glargine | 85 | 85 | 100 | 55a | 64.7 | 9 | 10.6 |
C: NPH/Lente | 90 | 88 | 97.8 | 61 | 67.8 | 4 | 4.4 | |
Davies 2014 | I: degludec | 301 | 280 | 93.0 | 176 | 58.5 | 32 | 10.6 |
C: detemir | 152 | 139 | 91.4 | 89 | 58.6 | 16 | 10.5 | |
Fulcher 2005 | I: glargine | 62 | 62a | 100 | 50 | 81 | 13a | 21 |
C: NPH | 63 | 59 | 93.7 | 54 | 86 | 16 | 25.4 | |
Heller 2009 | I: detemir | 299 | 291a | 97.3 | 256a | 97.3 | 54a | 18.1 |
C: glargine | 144 | 140 | 97.2 | 121 | 84.0 | 23 | 16.0 | |
Home 2005 | I: glargine | 292 | 260 | 89.0 | 178 | 61.0 | 31 | 10.6 |
C: NPH | 293 | 248 | 84.6 | 179 | 61.1 | 44 | 15.0 | |
Kobayashi 2007 | I: detemir | 196 | 178 | 92.7 | 133 | 69.3 | 2 | 1.0 |
C: NPH | 98 | 95 | 95.6 | 78 | 79.6 | 3 | 3.0 | |
Liu 2016 | I: glargine | 107 | 99 | 92.5 | 83 | 77.6 | 1 | 0.9 |
C: NPH | 54 | 51 | 94.4 | 42 | 77.8 | 1 | 1.9 | |
NCT00595374 | I: detemir | 75 | — | — | — | — | — | — |
C: NPH | 38 | — | — | — | — | — | — | |
NCT00605137 | I: detemir | 55 | 53a | 96.4 | — | — | 5 | 9.1 |
C: NPH | 27 | 27 | 100 | — | — | 3 | 11.1 | |
Pieber 2007 | I: detemir | 161 | 120 | 75.9 | 47 | 29.3 | 3 | 1.9 |
C: glargine | 159 | 108 | 70.1 | 50 | 31.4 | 12 | 7.8 | |
Porcellati 2004 | I: glargine | 61 | — | — | — | — | 0 | 0 |
C: NPH | 60 | — | — | — | — | 0 | 0 | |
PRESCHOOL | I: glargine | 61 | 61 | 100 | 59 | 96.7 | 4 | 6.6 |
C: NPH | 60 | 63 | 98.4 | 60 | 93.8 | 2 | 3.1 | |
Ratner 2000 | I: glargine | 264 | 251a | 95.1 | 204a | 77.3 | 23a | 8.7 |
C: NPH | 270 | 254 | 94.1 | 208 | 77.0 | 28 | 10.4 | |
Robertson 2007 | I: detemir | 232 | 223 | 96.1 | 174 | 75.0 | 37 | 15.9 |
C: NPH | 115 | 113 | 98.3 | 101 | 87.8 | 23 | 20.0 | |
Russell‐Jones 2004 | I: detemir | 491 | 448 | 93.3 | 339 | 70.6 | 31 | 6.5 |
C: NPH | 256 | 229 | 92.7 | 180 | 72.9 | 22 | 8.9 | |
Schober 2002 | I: glargine | 174 | 138 | 79.3 | 85 | 48.3 | 40 | 25.0 |
C: NPH | 175 | 138 | 78.9 | 89 | 50.9 | 50 | 28.8 | |
Standl 2004 | I: detemir | 236 | 184 | 80.3 | 134a | 58.5 | 20a | 8.7 |
C: NPH | 224 | 169 | 76.8 | 137 | 62.3 | 12 | 5.5 | |
SWITCH 1b | I: degludec | — | — | — | — | — | — | — |
C: glargine | — | — | — | — | — | — | — | |
Thalange 2013 | I: detemir | 177 | 146 | 82.5 | 100 | 56.5 | 3 | 1.7 |
C: NPH | 170 | 150 | 88.2 | 111 | 65.3 | 12 | 7.0 | |
Urakami 2017 | I: degludec | 9 | 9 | 100 | 2 | 22.2 | 0 | 0 |
C: glargine | 9 | 9 | 100 | 4 | 44.4 | 0 | 0 | |
Vague 2003 | I: Detemir | 301 | 271 | 90.0 | 198 | 65.8 | 24 | 8.0 |
C: NPH | 146 | 138 | 94.5 | 110 | 75.3 | 21 | 14.4 | |
—: denotes not reported aData from CSR. bNone of the information for this table was reported before cross‐over. C: comparator; CSR: clinical study report; I: intervention; N: number of participants; NPH: neutral protamine Hagedorn. |